▁F DA . ▁In ▁November ▁that ▁year ▁the ▁F DA ▁lifted ▁the ▁restrictions ▁it ▁had ▁placed ▁on ▁the ▁drug . ▁The ▁box ed ▁warning ▁about ▁heart ▁attack ▁was ▁removed ; ▁the ▁warning ▁about ▁heart ▁failure ▁remained ▁in ▁place . ▁ ▁Par ox et ine ▁( P ax il / S ero x at ) ▁ ▁G SK ▁was ▁f ined ▁for ▁prom oting ▁P ax il / S ero x at ▁( par ox et ine ) ▁for ▁tre ating ▁de pression ▁in ▁the ▁under - 1 8 s , ▁although ▁the ▁drug ▁had ▁not ▁been ▁approved ▁for ▁ped iat ric ▁use . ▁P ax il ▁had ▁US $ 4 . 9 7 b ill ion ▁world wide ▁sales ▁in ▁ 2 0 0 3 . ▁The ▁company ▁conducted ▁nine ▁clin ical ▁tri als ▁between ▁ 1 9 9 4 , ▁and ▁ 2 0 0 2 , ▁none ▁of ▁which ▁showed ▁that ▁P ax il ▁helped ▁children ▁with ▁de pression . ▁From ▁ 1 9 9 8 , ▁to ▁ 2 0 0 3 , ▁it ▁promoted ▁the ▁drug ▁for ▁the ▁under - 1 8 s , ▁pay ing ▁phys icians ▁to ▁go ▁on ▁all - exp enses ▁paid ▁tri ps , ▁five - star ▁hot els ▁and ▁sp as . ▁From ▁ 2 0 0 4 , ▁P ax il ' s ▁label , ▁along ▁with ▁those ▁of ▁similar ▁dru gs , ▁included ▁an ▁F DA - m and ated ▁box ed ▁warning ▁that ▁it ▁might ▁increase ▁the ▁risk ▁of ▁suic